Post hoc analysis of RATIONALE-306 in 358 patients with advanced oesophageal squamous-cell carcinoma and PD-L1 TAP ≥5%: tislelizumab plus chemotherapy vs placebo plus chemotherapy gave median OS 19.1 vs 10.0 months (HR 0.61); grade ≥3 TRAEs 70.2% vs 66.5%.
Secondary analysisn = 358
Tougeron et al. Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆